• Wondering if Inspire Medical Systems at around US$56.69 is a bargain or a value trap? This article focuses on what the current price really implies about the stock.
• The share price has seen mixed recent moves, with a 3.1% gain over the last 7 days, a 4.6% decline over 30 days, and year to date and 1 year returns of 38.6% and 60.8% declines respectively.
• Recent coverage has focused on how the share price performance over multiple time frames compares to broader market and industry moves, giving context to how sentiment toward Inspire Medical Systems has shifted. Other commentary has highlighted how investors are reassessing the balance between the company’s growth potential and the risks reflected in these returns.
• On Simply Wall St’s 6 point valuation checklist, Inspire Medical Systems currently scores a 5 out of 6. The rest of this article will walk through what different valuation methods say about that score, before finishing with a way to look at valuation that brings all of these pieces together.

Approach 1: Inspire Medical Systems Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. It is essentially asking what future cash the business might generate and what that stream is worth in today’s dollars.

For Inspire Medical Systems, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $77.5 million. Analysts provide detailed free cash flow estimates for several years, and Simply Wall St then extrapolates further, with projections reaching $230.3 million in 2035. All of these figures are in US$ and sit in the millions, not billions.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $134.62 per share. Compared with the recent share price of around $56.69, the model implies the stock is about 57.9% undervalued on this basis.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Inspire Medical Systems is undervalued by 57.9%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Inspire Medical Systems Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it connects what you pay for each share with the earnings that back it. Investors usually accept a higher P/E when they expect stronger earnings growth or see lower risk, and lean toward a lower P/E when growth expectations are more modest or risks appear higher.

Inspire Medical Systems currently trades on a P/E of 11.23x. That sits below the Medical Equipment industry average of 26.25x and well below the peer group average of 76.12x. On the surface, that suggests the market is putting a lower price on each dollar of Inspire Medical Systems earnings compared with many industry peers.

Simply Wall St’s Fair Ratio for Inspire Medical Systems is 15.66x. This is a proprietary estimate of what a reasonable P/E might be, taking into account factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it is tailored to the company, it can be more informative than a simple comparison with broad industry or peer averages.

Compared to this Fair Ratio of 15.66x, the current P/E of 11.23x points to the shares trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Inspire Medical Systems Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Think of a Narrative as your clear story for Inspire Medical Systems that ties together what you believe about its future revenue, earnings and margins with a forecast and fair value. Using Simply Wall St's Community page, millions of investors build these stories, compare their Fair Value to the current price to help decide whether to act, and see those views refresh automatically when new earnings, guidance or CMS coding news arrives. For example, one Inspire Medical Systems Narrative might lean toward the more optimistic fair value of about US$105.95 or even US$211.69 if you think reimbursement clarity, Inspire V adoption and SleepSync will support higher earnings over time. Another might sit nearer the more cautious US$60.00 view if you focus on reimbursement pressure, rollout risk and competition. Narratives let you see those different perspectives side by side so you can choose which one best matches your own expectations.

Do you think there's more to the story for Inspire Medical Systems? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.